The Drive to Discover. The Experience to Deliver.
Incyte's vision is to become a leading biopharmaceutical company by building a proprietary pipeline of novel small molecule drugs for serious unmet medical needs primarily in the area of oncology.
The field of oncology is evolving rapidly and transforming how cancer is and will be treated. With a growing pipeline that includes innovative compounds in three major oncology areas -- onco-inflammation, immuno-oncology and targeted therapies -- we believe Incyte is at the center of this transformation in cancer care.
Jakafi is a first-in-class JAK1/JAK2 inhibitor approved by the U.S. Food and Drug Administration (1) for treatment of people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF. Further, we are evaluating JAK inhibitors in multiple new indications and in combinations targeting solid tumors such as pancreatic, breast, colorectal and non-small cell lung cancer.
We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs.
Our pipeline also includes a novel immunotherapy, an oral IDO1 inhibitor, which is being evaluated alone and through multiple clinical collaborations. We also have a selective targeted therapy, an oral PI3K-delta inhibitor, which is in clinical development as monotherapy and in combination with one of our JAK inhibitors.
Incyte is rooted in rigorous science, and our highly productive chemists and biologists are continuing to identify new molecules that support our goal to deliver first- and/or best-in-class medicines capable of making a difference in health care, improving the lives of patients, and building sustainable value for our shareholders.
Incyte's corporate headquarters are located in Wilmington, Delaware.
- About Incyte
- Jakafi® (ruxolitinib)
- Disease Education